Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + pembrolizumab versus platinum-based chemotherapy for previously untreated HER2-expressing advanced urothelial carcinoma
MOH_2024-04-10_013366Phase 3Recruiting
- Sponsor
- Seagen Inc.
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of disitamab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Seagen Inc. Started Mar 2024; status: recruiting.
02
Drugs
disitamab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2024-04-10_013366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-10_013366.